Morgan Stanley Hcw Biologics Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Shares
2 transactions
Others Institutions Holding HCWB
# of Institutions
17Shares Held
1.16MCall Options Held
0Put Options Held
0-
Avantax Planning Partners, Inc.280KShares$114,6110.01% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$75,1360.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL181KShares$74,1320.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$54,1150.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX84.7KShares$34,7270.0% of portfolio
About HCW Biologics Inc.
- Ticker HCWB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,833,100
- Market Cap $14.7M
- Description
- HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...